BACKGROUND: The chemical structure of sulfonamide antibiotics and sulfonamide nonantibiotics can affect the potential for adverse reactions.
S ulfonamide antibiotics and sulfonamide nonantibiotics,such as sulfonylureas and thiazide diuretics, are well known to have the capacity to cause hypersensitivity reactions.l? Although in somepatients, possible cross-reactivity has occurred between a sulfonamide antibiotic and a sulfonamide nonantibiotic,"" the issue of cross-reactivity remains controversial. Available evidence suggests that sulfonamide antibiotics probably do not cross-react with sulfonamide nonantibictics.t'P Both sulfonamide antibiotics and nonantibiotics are compounds with a sulfonAuthor information provided at the endof the text.
amide moiety (SOzNH z). Not withstanding this same chemical structure, the group is very heterogeneous with respect to three-dimensional structures.
Sulfonamide antibiotic-induced hypersensitivity reactions involve a complex combination of metabolic andimmunological events. Sulfonamide antibiotics are derivatives of sulfanilamide (Figure la) . Theycontain an aromatic amine groupat the N4 position and a substituent at the NI position. The aromatic amine moietyis considered to be the trigger for serious drug reactions, due to the formationof reactive hydroxylamine intermediates and the subsequent haptenation product."Type I allergic reactions to sulfonamide antibiotics appearto be directed by the sub- 
Methods
The datafor this study wereobtained from the General Practice Research Database (GPRD), which contains the computerized medical stituents at the Nl position. The attachment of a 5-or 6-memberaromatic heterocyclic ring with at least 1 nitrogen to the sulfonamido-Nl and the presence of a singlemethyl group (~-position) on the second carbon atom are important allergenic determinants ( Figure Ib) .9,lt, 12 Sulfonamide nonantibiotics lack both the aromatic amine moiety and an Nl substituentwith a 5-or 6-member aromatic heterocyclicring ( Figure 2 ). On a chemical basis, it has been considered unlikely that the risk of a hypersensitivity reaction or allergicevent after use of a sulfonamide antibiotic and a nonantibiotic is the same.On the basisof the chemical structure, Johnson et al," divided sulfonamides into 3 groups: arylamines (a sulfonamide moiety connected to a benzene ring with an unsubstituted amine moiety at the N4 position, N4+) , nonarylamines (a sulfonamidemoiety connected to a benzene ring or other cyclic structure withoutthe amine moiety at the N4 position, N4-), and a group in which the sulfonamidemoiety was not directlyconnectedto the benzenering. However, in the nonarylamines group, they made no distinction betweensulfonamides thatlackeda 5-or 6-member aromatic heterocyclic ring (Nl") and sulfonamides that had a different typeof substituent at the Nl position (Nl").
In this study we classified sulfonamide drugs according to the absence or presence ofNl substituents and the absence or presence of an arylamine. The objective of this study was to determine whether the presence of Nl substituents and the aromatic amine moiety in sulfonamide drugs influence the occurrence of hypersensitivity reactions and allergic events. Wechose to conduct a studywith patients with diabetes mellitus (DM), as the frequency of use of sulfonamide drugs is relatively high withinsuchpatients. 
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Results
EXPOSURE ASSESSMENT
CASES ANDCONTROLS
The study basecomprised 141164patients witheithera diagnosis of OM or a prescription for a drug indicated for the treatment of OM. We identified 3362 (2.4%) cases with a record of a hypersensitivity reaction or allergic event. Urticaria was the most frequent allergic-like event (n = 1536,45.7%), followed by allergic rash (n = 961, 28.6%) and allergic reactions (n = 432,12.8%). Thirteen cases (0.4%) experienced anaphylactic shock; angioedema occurred in 120 patients (3.6%).
The characteristics of the study population are shown in Table 1 . The mean age ± SO was 59 ± 18 years (control group64 ± 18).Female gender, age 65 years or less,and a history or presence of an immune disease were associated withthe occurrence of hypersensitivity reactions and allergic events.
The association betweenthe use of sulfonamide drugs and the risk of hypersensitivity reactions and allergic eventsis shown in Table 2 . The prevalence of currentsulfonamide drug use was higheramongcases (40.2%) than among controls (28.0%), yielding a crude OR of 2.16 (95% CI 1.92to 2.43).This association persisted afteradjusting for sex, age, and immune disease state (OR 2.36, 95% CI 2.08 to 2.69).
Stratification according to the presence or absence of an Nl substituent or an arylamine showed thatthe current use of sulfonamide drugs with N1 +N4+ was mostclearly associatedwith the occurrence of hypersensitivity and allergic reactions (adjusted OR 3.71;95% CI 1.40 to 9.81). Current use of Nl' N4-and N1-N4-sulfonamide drugs was also associated with the occurrence of allergic reactions, althoughthe association was not as strong as that with N1+ N4+ sulfonamide drugs (Table 2 ). Current use of morethan one sulfonamide at the time yielded an OR of 3.05 (95% CI 2.44 to 3.82).Sex, age, and immune disease state were evaluated as effect modifiers. We also stratified on the
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Fromthe GPRD,we identified all patients witheithera diagnosis of diabetes (ICO-9 code 250) or a prescription for a drug indicated for the treatment of OM (ie, insulin and/ororal antidiabetic drugs)in the period from 1987 to 2001. Patients werefollowed from their firstdiagnosis of DM (afterpracticeup-to-standard) or the start of the data collection of the practice (whena patient hada firstdiagnosis of DM priorto thepractice'sup-to-standard date)to theend ofthe studyperiod.
Sulfonamidedrugs were classified by the presence of an NI substituent and an aromatic aminemoiety (Appendix II).The abbreviations NI+ and Nl-indicatethe presenceor absence, respectively, of a substituent at theNI position; N4+ andN4-indicate thepresence or absence, respectively, of an arylamine. Foreachpatient, we identified all prescriptionsforsulfonamide drugsin theyearbefore the index date.
Drugexposure wascategorized according to the timing of use in relation to the indexdate. Patients weredefined as currentuserswhenthey had received eithera prescription in a 14day time windowprior to the indexdateor the theoretical end dateof an earlierprescription was within or afterthis time window. If the end date of the last prescription was from 14to 365daysbeforethe index date,druguse wasdefined as past. No use wasdefined as no prescription of a sulfonamide within 1 yearbefore the index date.
Withinthe studybase, a nestedcase-control study was conducted. Casesweredefined as patients withat leastone diagnosis ofhypersensitivity or allergic reaction (eg, anaphylaxis, urticaria, angioedema, allergic rash, allergicdermatitis,and toxic epidermal necrolysis; for selected OXMISlRead codes,see Appendix I) during the study period. The date of the last recorded event of the outcomeeventwas the indexdate, because we also wanted to study the effectof priorhypersensitivity or allergic events. Foreachcase,up to 3 controls weresampled and matched on typeof OM,general practice, and index date.Potential controls were patients from the study basewhodid nothaveone of suchoutcomes during the study period.We made a distinction betweenpatients using insulinonly(type I) and thoseusingoral antidiabetic agentsonly or who had a diagnosis of DM without medication (type 2). Bothcasesand controls were eligible for inclusionif they had a minimumperiod of 365 daysof history in theGPRDprior to the index date.
presence or absence of NI substituents and the presence or absence of an arylamine in sulfonamide drugs. The associationbetween current use of a sulfonamide drug and allergic events was strongeramong males compared with females, as was age greater than 65 years (Table 3) . We found no difference in patients withor without an immune disease stateor a history of an allergic event.Amongcurrent users of a sulfonamide, the risk seemed most pronouncedamongpatients with OM using oral antidiabetic drugs (Table 3) . Wefound thattherisk of hypersensitivity or an allergic reaction afteruse of a sulfonamide drug was approximately 2 times greater than the risk for subjects who did not use any sulfonamide. Stratifying according to these substituents at the Nl and N4 positions showed that there was a differential risk between the groups of sulfonamides, although the difference was not statistically significant. The increase in riskwas mostpronounced for sulfonamidedrugs with an NI substituent with a 5-or 6-member aromatic heterocyclic ringand an arylamine(predominantly sulfonamide antibiotics). Thisfinding is in agreement withresults of studies that consider the Nl and N4 substituents of the sulfonamide antibiotics powerful predictors of immunologic response. 9 ,11,20 Although Nl" N4-and Nl-N4-sulfonamideagents (primarily sulfonylureas and diuretics, respectively) lack both the Nl substituent with a 5-or 6-memberaromatic heterocyclic ring and an arylamine, both groups were associated with an increasedrisk of hypersensitivity and allergic reactions. BothNl + N4-and NI-N4-sulfonamides are mostoften used chronically. Still, we found a twofold increaseof the risk of an allergic eventassociated with current use of these agents. Current use of more than one sulfonamide increased the risk of a hypersensitivity or allergic reaction3 times compared withtheriskin nonusers. Risk estimatesdid not differ betweenpatients with (a history of) immune diseases or a previous allergic event. However, stratification according to age and sex didreveal differences in risk.It has been suggested thatfemale sex is a risk factor for the occurrence of adverse drug reactions. 18.19,21 However, our findings do not support those data. Wedid identify an increased risk of an allergic reaction in patients olderthan 65 years with DM. Thisresultis consistent with those of studies suggesting that adverse reactions are more common in elderly patients. Z2 ,23 In patients with type 2 DM who are using oral antidiabeticdrugs, therisk of a hypersensitivity reaction associated with current use of a sulfonamide agentwashigher than in patients with type I DM and in those with a diagnosis DM whowere not receiving drug therapy. The numberof patients usingNI +N4+ sulfonamide drugs was small,but the association was also presentin the much largergroup of'Nl" N4-sulfonamide drug users.
There are potential methodologic limitations to our study. In our casedefinition, we selected codesfor hypersensitivity and allergic reactions and excluded codes that suggested non-unique causes. Therefore, it is possible that the lists of codes in Appendix I omittedcodes for hypersensitivity reactions and allergic events. Misclassification withrespect to therecording of diagnosis of hypersensitivity reactions and allergic events cannotbe excluded, but it seemsunlikely that misclassification was differential between cases andcontrols.
The timing of the outcome events was an important factor.The potential immunologic reaction related to sulfonamide antibiotics usually develops within 1-3 daysof initial medication; the hypersensitivity reaction requiring the presence of an arylamine has a delayed onset, usually within 7-14 days.9.10 Hypersensitivity reactions caused by some sulfonamide drugs (NI+ N4-) usually occur in the first 6-8 weeks of therapy. Because most of the outcome events are milddermatologic endpoints, it is possible that those events were not diagnosed or not reporteddirectly aftertheonsetof theevents.
Wedid compute theOR and95% CI forriskof a hypersensitivity reaction or allergic event withina 30 day time window priorto the indexdate. The ORsand95% CIs did not differsubstantially (datanot shown). Furthermore, as dermatologic events are known adverse effects of sulfonamide drugs,we cannotexclude the possibility that diagnostic suspicion bias accounts for partof theobserved outcome events.There could also have been other variables that we could not control; therefore, residual confounding is possible.
This study was conducted among patients withDM becausethe use of sulfonamides is usually relatively highin such patients. Toour knowledge, patients withDM are not at greater risk for hypersensitivity reactions after use of sulfonamide drugs than arepatients whoare notdiabetic. bStatlstfcally sIgnIficant difference (p < 0.05).
Differencein Risks ofAllergicReactionto SulfonamideDrugs Basedon ChemicalStructure
Previous reports that mention the risk of hypersensitivity reactions after use of sulfonamides do not categorize theseagents according to their substituents. Recategorizing these medications in the defined chemical structurecategories could be helpful to obtain a new perspective on the problemof "sulfa" aJlergy and/orcross-reactivity between drugswith a sulfonamide moiety. 
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In this study we used an innovative manner to examine adverse drug reactions by using chemical structures instead of a traditional pharmacology-based classification to assess exposure. Although our results did not show an obviousdifference in risk of a hypersensitivity or allergic reaction after using a sulfonamide drug classified according to substituents at the Nl and N4 positions. we believethat structure-activity relationships related to drug exposure will playa majorrole in the future.
Furtherresearch is needed to establish whethera possible association exists between the presence. or absence of substituents of sulfonamide drugs and the occurrence of hypersensitivity reactions.
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EXTRACfO TRASFONDO: La estructura qufrnica de losantibi6ticos y no-antibi6ticos sulfamidas pueden afectar el potencial parael desarrollo de reacciones adversas.
OBJETIVO: Determinar si diferencias qufmicas de varlasdrogas sulfamidas influencian el riesgo de eventos alergicos. Mtrooos: Un estudio de caso-control fueconducido en pacientes con diabetes usando datosde la "General Practice Research Database." Los casosfueron definidos comopacientes que tuvieron unadiagnosis de hipersensibilidad 0 reacci6n alergica, La fechadel ultimo acontecimiento alergico fue la fechaIndice, Los pacientes control fueron pareados de acuerdo a la pracdca medica, tipode diabetes, y fecha fndice. El usoactual de sulfamidas fue definido comosu usoen una ventana temporal de 14dfasantes de la fechafndice. Lassulfamidas fueron clasificadas segdn la presencia u ausencia de sustitutos al Nl (NI+/ Nl-) y/o de un arylamine en la posici6n N4 (N4+ / N4-). Se utiliz6 regresi6n logfstica condicional paraestimar la fuerza de la asociaci6n y estefue expresado comoproporci6n de probabilidad (oddsratios, OR)e intervalos de confidencia de 95%(95%CI).
RESULTADOS: Por10 general, el uso actual de sulfamidas Nl +N4+ estaba asociado con la ocurrencia de hipersensibllldad y reacciones alergicas (OR ajustada 3. . Le sexeet rage semblent stre des modificateurs de l'effet,n n'y a pasde preuve claired'une modification de l'effetpar l'etatimmunitaire du patient.
CONCLUSIONS: Bienqu'aucune difference importante n'ait ete noteeentre les groupes, ceneapproche est une nouvelle facond'examiner leseffets indesirables auxmedicaments en utilisant la structure chimique au lieu de la c1asse therapeutique pourcaraeteriser I'exposition.
